Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study.

Authors :: Hattori Y
Kojima T
Kaneko A
Kida D
Hirano Y
Fujibayashi T
Terabe K
Yabe Y
Miyake H
Kato T
Takagi H
Hayashi M
Ito T
Kanayama Y
Oguchi T
Takahashi N
Ishikawa H
Funahashi K
Ishiguro N
Source :: The Journal of rheumatology [J Rheumatol] 2016 Aug; Vol. 43 (8), pp. 1475-9. Date of Electronic Publication: 2016 Jun 15.
Publication Year :: 2016
Abstract: Objective: To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).<br />Methods: All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.<br />Results: The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.<br />Conclusion: Concomitant MTX contributes to the longterm efficacy of ADA therapy.

Subjects :: Adalimumab therapeutic use
Adult
Aged
Antirheumatic Agents therapeutic use
Female
Humans
Male
Methotrexate therapeutic use
Middle Aged
Registries
Risk Factors
Treatment Outcome
Adalimumab adverse effects
Antirheumatic Agents adverse effects
Arthritis, Rheumatoid drug therapy
Patient Dropouts

Full Text Access

Tools